The abstract is read at the publisher; the summary is JClub's.
Molecular glue degraders are expanding targeted protein degradation beyond cereblon by leveraging new E3 ligases, with multimeric CRLs offering modular blueprints for precision targeting.
- Why it matters: Many disease-associated proteins remain undruggable because they lack catalytic pockets or are dynamic and disordered, limiting conventional small-molecule approaches. Molecular glue degraders aim to overcome this by enabling selective elimination through E3 ligase–substrate stabilization.
- What they did: This review synthesizes advances in ligase-substrate recognition, structural principles, and rational glue design, emphasizing the shift from CRBN toward newly discovered effector ligases. It also connects MGD design to synthetic lethality and resistance frameworks for next-generation TPD.
- The result: The field is positioned to use the full spectrum of E3 ligases as a platform for glue-based therapeutics, with CRLs supporting precision targeting and design strategies addressing resistance. This provides a basis for developing next-generation TPD therapies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.